Internal Medicine · Miami, FL
NPI
1851344014
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
8335 NE 2nd Ave
Miami, FL, 33138
Phone (305) 757-0113
Groups this clinician bills Medicare through
Medicare paid, 2024
$397K
42,853 services
Medicare patients, 2024
82
Average age 55
Drug cost, 2024
$2.0M
2,924 prescriptions
Company payments, 2025
$1,265
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Gershwin T Blyden was code J0131 (injection, acetaminophen, not otherwise specified,10 mg), 10,136 times for 21 patients. In total Gershwin T Blyden billed 42,853 services in 51 codes, and Medicare paid $397K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-01-12.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0131 Injection, acetaminophen, not otherwise specified,10 mg | Office | 10,136 | 21 | $0.04 | $389 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 5,056 | 28 | $0.07 | $375 |
| 96375 Injection Administration | Office | 5,032 | 29 | $12.11 | $61K |
| 96361 Intravenous Infusion, Hydration | Office | 1,984 | 29 | $9.75 | $19K |
| J1170 Injection, hydromorphone, up to 4 mg | Office | 1,983 | 24 | $3.06 | $6,064 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 1,935 | 29 | $0.66 | $1,269 |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 1,530 | 24 | $0.49 | $745 |
| J1171 Injection, hydromorphone, 0.1 mg | Office | 1,510 | 13 | $0.07 | $101 |
| 99214 Office E&M - Established | Office | 1,386 | 79 | $100.68 | $140K |
| 81003 Clinical Chemistry | Office | 1,346 | 34 | $2.17 | $2,918 |
| 96374 Injection Administration | Office | 1,335 | 29 | $28.85 | $39K |
| 85018 Blood Count | Office | 1,182 | 32 | $2.32 | $2,742 |
| 82962 Clinical Chemistry | Office | 1,148 | 33 | $3.20 | $3,675 |
| 93000 Electrocardiogram | Office | 965 | 33 | $11.51 | $11K |
| J7060 5% dextrose/water (500 ml = 1 unit) | Office | 913 | 25 | $1.41 | $1,292 |
By year: 2022 $147K for 11,523 services; 2023 $434K for 44,230 services; 2024 $397K for 42,853 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 1,346 | 34 | $2.17 | $2,918 |
| 85018 Blood Count | 1,182 | 32 | $2.32 | $2,742 |
| 82962 Clinical Chemistry | 1,148 | 33 | $3.20 | $3,675 |
| 85025 Blood Count | 865 | 32 | $7.05 | $6,097 |
| 81025 Clinical Chemistry | 675 | 21 | $8.41 | $5,677 |
| 36415 Venipuncture Blood Collection | 14 | 12 | $8.65 | $121 |
Medicare prescription drug claims, 2024
In 2024, the drug Gershwin T Blyden prescribed most often to Medicare patients was Oxycodone Hcl, with 301 prescriptions and refills. In total Gershwin T Blyden wrote 2,924 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Oxycodone Hcl Generic | 301 | 303 | 36 | $14K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 111 | 111 | 22 | $4,749 |
| Cyclobenzaprine Hcl Generic | 89 | 90 | 26 | $728 |
| Morphine Sulfate Er Morphine Sulfate | 82 | 84 | 16 | $6,317 |
| Hydroxyurea Generic | 79 | 119 | 21 | $3,019 |
| Gabapentin Generic | 78 | 101 | 25 | $786 |
| Temazepam Generic | 71 | 71 | Under 11 | $747 |
| Oxycontin Oxycodone Hcl | 68 | 68 | Under 11 | $129K |
| Prednisone Generic | 65 | 66 | 13 | $246 |
| Atorvastatin Calcium Generic | 61 | 171 | 20 | $408 |
| Abiraterone Acetate Generic | 58 | 58 | Under 11 | $111K |
| Amlodipine Besylate Generic | 57 | 168 | 19 | $175 |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 54 | 104 | 15 | $530 |
| Nifedipine Er Nifedipine | 47 | 118 | 17 | $730 |
| Hydrochlorothiazide Generic | 43 | 105 | Under 11 | $99.77 |
Brand drugs: - claims; generic drugs: 2,542 claims; opioid claims: 706.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Gershwin T Blyden $1,265 ($1,265 in general payments such as food, travel and fees) from 8 companies. The largest payer was Novartis Pharmaceuticals Corporation with $991.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.